HFM
REGN icon

Harvest Fund Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Harvest Fund Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.11M Sell
7,917
-37
-0.5% -$28.3K 0.26% 74
2025
Q4 		$6.14M Buy
7,954
+1,561
+24% +$1.06M 0.23% 82
2025
Q3 		$3.6M Buy
6,393
+366
+6% +$207K 0.15% 103
2025
Q2 		$3.16M Sell
6,027
-773
-11% -$431K 0.15% 108
2025
Q1 		$4.31M Buy
6,800
+440
+7% +$303K 0.21% 84
2024
Q4 		$4.39M Buy
6,360
+1,366
+27% +$1.15M 0.2% 85
2024
Q3 		$5.25M Buy
4,994
+1,523
+44% +$1.69M 0.31% 59
2024
Q2 		$3.65M Sell
3,471
-170
-5% -$165K 0.26% 62
2024
Q1 		$3.5M Buy
3,641
+2,449
+205% +$2.33M 0.31% 61
2023
Q4 		$1.03M Buy
1,192
+101
+9% +$83.2K 0.16% 77
2023
Q3 		$898K Buy
1,091
+479
+78% +$376K 0.16% 78
2023
Q2 		$440K Sell
612
-26
-4% -$20K 0.09% 119
2023
Q1 		$524K Buy
638
+53
+9% +$40K 0.12% 95
2022
Q4 		$420K Buy
585
+145
+33% +$107K 0.11% 118
2022
Q3 		$303K Sell
440
-81
-16% -$51K 0.09% 128
2022
Q2 		$308K Hold
521
– – 0.09% 114
2022
Q1 		$363K Sell
521
-39
-7% -$24.7K 0.08% 123
2021
Q4 		$360K Buy
560
+153
+38% +$94.1K 0.06% 146
2021
Q3 		$246K Buy
407
+306
+303% +$190K 0.06% 120
2021
Q2 		$58K Sell
101
-35
-26% -$17.7K 0.01% 387
2021
Q1 		$64K Sell
136
-178
-57% -$86.7K 0.01% 348
2020
Q4 		$151K Sell
314
-736
-70% -$397K 0.01% 187
2020
Q3 		$635K Buy
1,050
+528
+101% +$320K 0.05% 69
2020
Q2 		$317K Buy
522
+72
+16% +$40.9K 0.03% 98
2020
Q1 		$219K Buy
+450
New +$186K 0.03% 115
2019
Q2 		– Sell
-425
Closed -$175K – 418
2019
Q1 		$175K Buy
425
+191
+82% +$78.7K 0.03% 127
2018
Q4 		$87K Buy
+234
New +$85.6K 0.02% 194
2017
Q4 		– Sell
-58
Closed -$26K – 245
2017
Q3 		$26K Hold
58
– – ﹤0.01% 185
2017
Q2 		$28K Buy
+58
New +$25.4K ﹤0.01% 193

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Harvest Fund Management's REGN Position: Q1 2026 in Review

Harvest Fund Management reduced its Regeneron Pharmaceuticals (REGN) stake by 0.47% in Q1 2026, selling an estimated $28.3K and leaving 7,917 shares worth $6.11M. The position accounts for 0.26% of the portfolio, ranked #74.

Harvest Fund Management first reported a position in REGN in Q2 2017 and has held it in 29 quarters since. The position peaked at $6.14M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Harvest Fund Management held 7,917 shares of Regeneron Pharmaceuticals worth $6.11M as of Q1 2026.
  • Harvest Fund Management sold 37 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $28.3K.
  • Regeneron Pharmaceuticals made up 0.26% of Harvest Fund Management's portfolio in Q1 2026, its #74 holding.
  • Harvest Fund Management first reported a position in Regeneron Pharmaceuticals in Q2 2017 and has held it in 29 quarters since.
  • Harvest Fund Management's Regeneron Pharmaceuticals position peaked at $6.14M in Q4 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Harvest Fund Management's 13F filing for Q1 2026, filed 14 May 2026.